HC Wainwright & Co. Upgrades NovoCure to Buy, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has upgraded NovoCure (NASDAQ:NVCR) from Neutral to Buy, raising the price target from $24 to $30.
October 16, 2024 | 10:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has upgraded NovoCure from Neutral to Buy, increasing the price target from $24 to $30. This upgrade suggests a positive outlook for NovoCure's stock.
The upgrade from Neutral to Buy by HC Wainwright & Co. indicates increased confidence in NovoCure's future performance. The raised price target from $24 to $30 suggests potential upside in the stock price, likely leading to positive investor sentiment and a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100